Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24217473 | 0.87 | — | — | |
| SCHEMBL24212076 | 0.87 | — | — | |
| SCHEMBL11225412 | 0.82 | EPHX1 (0.48) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| Methylene Chloride SCHEMBL25302622 | 0.79 | EPHX1 (0.37) | EPHX1 | |
| SCHEMBL4015606 | 0.78 | EPHX1 (0.44) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL4422113 | 0.78 | EPHX1 (0.44) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL4957639 | 0.78 | EPHX1 (0.44) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL1616204 | 0.76 | EPHX1 (0.43) | EPHX1ALDH1A1TP53DPP4KDM4E | |
| SCHEMBL3634705 | 0.76 | EPHX1 (0.43) | EPHX1ALDH1A1TP53KDM4EMAPT | |
| SCHEMBL1712104 | 0.75 | EPHX1 (1.00) | EPHX1ALDH1A1TP53DPP4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513825-B1 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Dept of Health and Human Services (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1909780-A2 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | Sequella, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007005896-A2 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
| EP-1513825-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | Department of Health and Human Services (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | PROTOPOPOVA MARINA NIKOLAEVNA (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-25 | — | — | US | disclosed |
| WO-2003096989-A2 | ANTI TUBERCULAR DRUG: COMPOSITIONS AND METHODS | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | EPHX1 226/4885ALDH1A1 1876/4885TP53 652/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | EPHX1 222/4885ALDH1A1 1029/4885TP53 1489/4885 |
| US-20030236225-A1 | Methods of use and compositions for the diagnosis and treatment of infectious disease | TERT, C5, DERA | EPHX1 223/4885ALDH1A1 1103/4885TP53 818/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | EPHX1 314/4885ALDH1A1 1277/4885TP53 1207/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | EPHX1 314/4885ALDH1A1 1277/4885TP53 1207/4885 |
| US-20040033986-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | EPHX1 314/4885ALDH1A1 1277/4885TP53 1207/4885 |
| US-20040019117-A1 | Anti tubercular drug: compostions and methods | TYMS, TERT, TYMP | EPHX1 572/4885ALDH1A1 1691/4885TP53 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.